Laura M. Shelton, Ph.D. - Publications

Institution:
Boston College, Newton, MA, United States
Area:
metabolic therapy

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Seyfried TN, Arismendi-Morillo G, Zuccoli G, Lee DC, Duraj T, Elsakka AM, Maroon JC, Mukherjee P, Ta L, Shelton L, D'Agostino D, Kiebish M, Chinopoulos C. Metabolic management of microenvironment acidity in glioblastoma. Frontiers in Oncology. 12: 968351. PMID 36059707 DOI: 10.3389/fonc.2022.968351  0.72
2019 Seyfried TN, Shelton L, Arismendi-Morillo G, Kalamian M, Elsakka A, Maroon J, Mukherjee P. Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma? Neurochemical Research. PMID 31025151 DOI: 10.1007/S11064-019-02795-4  0.644
2018 Flores RE, Brown AK, Taus L, Khoury J, Glover F, Kami K, Sarangarajan R, Walshe T, Narain NR, Kiebish MA, Shelton L, Chinopoulos C, Seyfried TN. Mycoplasma infection and hypoxia initiate succinate accumulation and release in the VM-M3 cancer cells. Biochimica Et Biophysica Acta. PMID 29580805 DOI: 10.1016/J.Bbabio.2018.03.012  0.681
2017 Kremer JC, Prudner BC, Lange SE, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, et al. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers. Cell Reports. 18: 991-1004. PMID 28122247 DOI: 10.1016/J.Celrep.2016.12.077  0.512
2016 Samanta D, Park Y, Andrabi SA, Shelton LM, Gilkes DM, Semenza GL. PHGDH Expression is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance and Lung Metastasis. Cancer Research. PMID 27280394 DOI: 10.1158/0008-5472.Can-16-0530  0.458
2016 Coloff JL, Murphy JP, Braun CR, Harris IS, Shelton LM, Kami K, Gygi SP, Selfors LM, Brugge JS. Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells. Cell Metabolism. PMID 27133130 DOI: 10.1016/J.Cmet.2016.03.016  0.381
2015 Tedeschi PM, Johnson-Farley N, Lin H, Shelton LM, Ooga T, Mackay G, Van Den Broek N, Bertino JR, Vazquez A. Quantification of folate metabolism using transient metabolic flux analysis. Cancer & Metabolism. 3: 6. PMID 26023330 DOI: 10.1186/S40170-015-0132-6  0.365
2015 Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, Chudnovsky Y, Pacold ME, Chen WW, Cantor JR, Shelton LM, Gui DY, Kwon M, Ramkissoon SH, Ligon KL, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 520: 363-7. PMID 25855294 DOI: 10.1038/Nature14363  0.527
2014 Akgoc Z, Shelton LM, Ryan D, Zhu X, Seyfried TN. Abstract 4113: Restricted ketogenic diet reduces growth and distant organ metastasis in the murine VM-M3 metastatic tumor model Cancer Research. 74: 4113-4113. DOI: 10.1158/1538-7445.Am2014-4113  0.519
2013 Seyfried TN, Shelton LM, Huysentruyt LC. The VM mouse model of glioblastoma multiforme Neuromethods. 77: 39-55. DOI: 10.1007/7657_2012_34  0.707
2012 Seyfried TN, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Research. 100: 310-26. PMID 21885251 DOI: 10.1016/J.Eplepsyres.2011.06.017  0.786
2011 Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biochimica Et Biophysica Acta. 1807: 577-94. PMID 20804725 DOI: 10.1016/J.Bbabio.2010.08.009  0.77
2010 Shelton LM, Huysentruyt LC, Mukherjee P, Seyfried TN. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. Asn Neuro. 2: e00038. PMID 20664705 DOI: 10.1042/An20100002  0.774
2010 Seyfried TN, Shelton LM, Mukherjee P. Does the existing standard of care increase glioblastoma energy metabolism? The Lancet. Oncology. 11: 811-3. PMID 20634134 DOI: 10.1016/S1470-2045(10)70166-2  0.534
2010 Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. International Journal of Cancer. Journal International Du Cancer. 127: 2478-85. PMID 20473919 DOI: 10.1002/Ijc.25431  0.79
2010 Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutrition & Metabolism. 7: 7. PMID 20181022 DOI: 10.1186/1743-7075-7-7  0.618
2010 Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. Journal of Neuro-Oncology. 99: 165-76. PMID 20069342 DOI: 10.1007/S11060-010-0115-Y  0.79
2010 Huysentruyt LC, Shelton LM, Seyfried TN. Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. International Journal of Cancer. Journal International Du Cancer. 126: 65-72. PMID 19536778 DOI: 10.1002/Ijc.24649  0.787
2010 Shelton LM, Huysentruyt LC, Seyfried TN. Abstract 5421: Targeting glucose and glutamine for the metabolic management of systemic metastatic cancer Cancer Research. 70: 5421-5421. DOI: 10.1158/1538-7445.Am10-5421  0.774
2010 Shelton LM, Strelko CL, Roberts MF, Seyfried TN. Abstract 53: Krebs cycle substrate-level phosphorylation drives metastatic cancer cells Cancer Research. 70: 53-53. DOI: 10.1158/1538-7445.Am10-53  0.494
2008 Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. International Journal of Cancer. Journal International Du Cancer. 123: 73-84. PMID 18398829 DOI: 10.1002/Ijc.23492  0.795
2008 Mukherjee P, Faber AC, Shelton LM, Baek RC, Chiles TC, Seyfried TN. Thematic review series: sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. Journal of Lipid Research. 49: 929-38. PMID 18287616 DOI: 10.1194/Jlr.R800006-Jlr200  0.74
Show low-probability matches.